Background There is currently a lack of clarity on the length and type of immune responses to SARS-CoV-2 infection. The predominant immune response to infection in humans is thought to be due to their presumed lack of immunological experience with SARS-CoV-2. Objective This study aimed to use IgG and IgM titre of SARS-CoV-2 for vaccine efficacy assessment. Materials and methods This study was conducted on a cohort of 82 individuals; 41 subjects were positive COVID-19 and 41 subjects taking COVID-19 vaccine in Zagazig, Sharkia. All patients had comprehensive medical histories taken, physical exams performed, and blood samples taken in order to evaluate the following: ELISA-based quantitative serological IgM and IgG levels were measured three weeks following the second dose of the Sinopharm and AstraZeneca vaccines, in addition to a full blood count. Results The results showed that IgM and IgG were significantly higher among Infected subjects compared to vaccinated subjects. We also noted that there was no significant association between IgM & IgG and age & gender or comorbidities. Regarding side effects, flu symptoms were the most prevalent side effects that were found in 26.8% of the patients, shoulder edema in 14.6% and local irritation in 2.4%. Conclusions IgG and IgM are good parameters for COVID-19 infection follow up and a significant indictor for vaccination effectiveness for prevention of transmission of SARS-Cov-2.